Dr. Katrin Schöneweis

Randomized open-label study of Myrcludex B plus PEG-IFNalpha in patients with HBeAg negative chronic Hepatitis B co-infected with Hepatitis delta

Virus-host interactions: Analyses of antiviral activity of drugs against the Hepatitis B virus Identification and characterization of host factors post-translational analyses of the Hepatitis B virus receptor Hepatocyte-specific drug targeting using Hepatitis B envelope protein-derived peptides: solid phase synthesis chemical coupling of substances to peptides supervision and mentoring: Interns, Bachelor- and Master-students Assistance in clinical trial: Myrcludex B

• 3 month research residence at the Department of Clinical Immunology, Tongji Hospital, Huazhong University of Science and Technology Wuhan, China • siRNA silencing approach: targeting the X protein of Woodchuck Hepatitis virus • animal study in Woodchucks (Marmota monax): Characterization of REP2139 and REP2055 by REPLICor • in vivo delivery system for siRNA/shRNA: Adeno-Associated Virus, production and characterization

Topic of diploma thesis: " U1shRNA-mediated gene therapy approach to cure human 5´splice site mutations" - gene therapy strategy to suppress pathogenic 5´splice site mutations

Identification and characterization of the Cyp4L4 gene, an isoform of the Cytochrom P450, in trichoplusia ni cells.

Virology, Parasitology, Toxicology, stem cell research